In the realm of healthcare and wellness, it is important to strike a balance between creating benefits and alleviating suffering. Sarcopenia is characterized by a general loss of muscle. Most of the sarcopenia patients are the elders. People with sarcopenia suffer from difficulty in mobility. However, current treatments for sarcopenia are ineffective and inefficient. Therefore, we attempt to develop Sarcotreat, an engineered live biotherapeutic product that treats sarcopenia. On this page, we created our own business canvas, which includes identifying customer segments, crafting a compelling value proposition, and understanding the nuances of customer needs and challenges. Our focus is on creating our own innovative solutions. In this context, our goal is to generate revenue by ensuring affordability, efficiency, and ease of use, while addressing potential challenges that are related to product suitability and effectiveness. This holistic approach emphasizes adherence to medication precautions and a clear understanding of medication procedures with the ultimate goal of improving the overall health of our valued clients.

Value proposition canvas

We created a value proposition canvas to craft a narrative that explains the clinical, economic, and societal value of a drug within the broader treatment context.

Business model canvas

The primary objective of this business model canvas is to comprehensively assess our products from multiple angles, encompassing Key Activities, Key Resources, Value Propositions, Customer Relationships, Channels, Customer Segments, Key Partners, Cost Structure, and Revenue Streams. Within each of these categories, our special emphasis is on delving into the core strengths and unique qualities of our products, offering our clients a deeper insight into how we effectively address the challenges of sarcopenia and the intricate development process behind our solution.


   As more and more nations became aging societies and the advancement of medical treatment, the global market began to concentrate on the healthcare system for the old and middle-aged population. Sarcopenia, among the old and middle generations, is a common symptom that causes the loss of muscle mass and the dysfunction of muscles. 
   The worldwide sarcopenia treatment market had a total worth of $2,577 million in 2020 and is anticipated to grow to $4,704 million by 2030, with a compound annual growth rate (CAGR) of 6.1%. In addition, there is currently no competitor in the market; none of the pharmaceutical companies have successfully developed an effective drug for sarcopenia. Hence, we believe this is our opportunity to make a great impact on0p the market and industry.